No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
BIIB250117P143000
- 2.20
- +0.60+37.50%
15min DelayClose Jan 15 16:00 ET
2.20High2.20Low
2.20Open1.60Pre Close10 Volume22 Open Interest143.00Strike Price2.20KTurnover37.67%IV0.14%PremiumJan 17, 2025Expiry Date2.00Intrinsic Value100Multiplier1DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.7146Delta0.1003Gamma54.76Leverage Ratio-0.4229Theta-0.0038Rho-39.13Eff Leverage0.0306Vega
Intraday
- 5D
- Daily
News
Oppenheimer Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $255
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating
Biogen Announces New Chief Accounting Officer Appointment
BMO Capital Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $164
Biogen's Hold Rating: Navigating Challenges in Alzheimer's Treatments and Pipeline Development
The CEO of Bojian stated that there is no need to seek additional trades to develop the business.
On January 15, at the JPMorgan annual Medical Care conference, Biogen's CEO Chris Viehbacher stated that by 2028, revenue from new products is expected to exceed current sales, and there is no need to seek additional Trades for Business development. Viehbacher explained that the Analyst community's perspective is that Biogen's future depends on our next Trade, which the company internally does not agree with. Last Friday, Biogen proposed to acquire its marketing partner Sage Therapeutics for its postpartum depression treatment.